{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:37:34Z","timestamp":1783971454253,"version":"3.55.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,11,24]],"date-time":"2011-11-24T00:00:00Z","timestamp":1322092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical outcomes for patients with <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>aposi's sarcoma (<jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content>) using nonnucleoside reverse transcriptase inhibitor (<jats:styled-content style=\"fixed-case\">NNRTI<\/jats:styled-content>)\u2010based highly active antiretroviral therapy (<jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content>) in resource\u2010limited settings have not previously been described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients aged \u2265\u200918 years, who initiated <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> in the <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>ome\u2010<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ased <jats:styled-content style=\"fixed-case\">AIDS C<\/jats:styled-content>are (<jats:styled-content style=\"fixed-case\">HBAC<\/jats:styled-content>) project in <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>ororo, <jats:styled-content style=\"fixed-case\">U<\/jats:styled-content>ganda, between <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ay 2003 and <jats:styled-content style=\"fixed-case\">F<\/jats:styled-content>ebruary 2008 and were diagnosed with <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> at baseline or during follow\u2010up. We examined independent risk factors for having either prevalent or incident <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> and risk factors for death among patients with <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1121 study subjects, 17 (1.5%) were diagnosed with prevalent <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> and 18 (1.6%) with incident <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> over a median of 56.1 months of follow\u2010up. <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> was associated with male sex [adjusted odds ratio (<jats:styled-content style=\"fixed-case\">AOR<\/jats:styled-content>) 2.41; 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 1.20\u20134.86] and baseline <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 cell count &lt;\u200950 cells\/\u03bc<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">AOR<\/jats:styled-content> 3.25; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.03\u201310.3). Eleven (65%) of 17 patients with prevalent <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> and 13 (72%) of 18 patients with incident <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> experienced complete regression (<jats:styled-content style=\"fixed-case\"><jats:italic>P<\/jats:italic><\/jats:styled-content>\u2009=\u20090.137). Eighteen (64%) of 28 patients who remained on <jats:styled-content style=\"fixed-case\">NNRTI<\/jats:styled-content>\u2010based <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> experienced regression of their <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> and six (86%) of seven patients who were switched to protease inhibitor\u2010containing <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> regimens had regression of their <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\"><jats:italic>P<\/jats:italic><\/jats:styled-content>\u2009=\u20090.23). Mortality among those with <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> was significantly associated with visceral disease (hazard ratio 19.22; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 2.42\u2013152).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Prevalent or incident <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> was associated with 30% mortality. The resolution of <jats:styled-content style=\"fixed-case\">KS<\/jats:styled-content> lesions among individuals who initiated <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">NNRTI<\/jats:styled-content>\u2010based regimens was similar to that found in studies using only protease inhibitor\u2010based <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2011.00955.x","type":"journal-article","created":{"date-parts":[[2011,11,24]],"date-time":"2011-11-24T05:54:34Z","timestamp":1322114074000},"page":"166-171","source":"Crossref","is-referenced-by-count":20,"title":["Clinical outcomes of <scp>HIV<\/scp>\u2010infected patients with <scp>K<\/scp>aposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor\u2010based antiretroviral therapy in <scp>U<\/scp>ganda"],"prefix":"10.1111","volume":"13","author":[{"given":"FM","family":"Asiimwe","sequence":"first","affiliation":[{"name":"Global AIDS Program US Centers for Disease Control and Prevention (CDC) Uganda  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DM","family":"Moore","sequence":"additional","affiliation":[{"name":"Global AIDS Program US Centers for Disease Control and Prevention (CDC) Uganda  Entebbe Uganda"},{"name":"British Columbia Centre for Excellence in HIV\/AIDS  Vancouver Canada"},{"name":"Department of Medicine, Faculty of Medicine University of British Columbia  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Were","sequence":"additional","affiliation":[{"name":"Global AIDS Program US Centers for Disease Control and Prevention (CDC) Uganda  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Nakityo","sequence":"additional","affiliation":[{"name":"Global AIDS Program US Centers for Disease Control and Prevention (CDC) Uganda  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Campbell","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS Prevention US CDC  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Barasa","sequence":"additional","affiliation":[{"name":"Global AIDS Program US Centers for Disease Control and Prevention (CDC) Uganda  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mermin","sequence":"additional","affiliation":[{"name":"Global AIDS Program US Centers for Disease Control and Prevention (CDC) Uganda  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Kaharuza","sequence":"additional","affiliation":[{"name":"Global AIDS Program US Centers for Disease Control and Prevention (CDC) Uganda  Entebbe Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00120-4"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10817"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200306010-00015"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910540106"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199912240-00010"},{"key":"e_1_2_6_7_1","first-page":"1069","article-title":"AIDS\u2010associated Kaposi's sarcoma in Northeastern Nigeria","volume":"47","author":"Kagu MB","year":"2006","journal-title":"Singapore Med J"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009290-00006"},{"key":"e_1_2_6_9_1","first-page":"S31","article-title":"Kaposi's sarcoma and non\u2010Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants","volume":"21","author":"Rabkin CS","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005260-00010"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02818.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6792"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-13-23"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00161-6"},{"key":"e_1_2_6_15_1","first-page":"779","article-title":"Long\u2010term clinical outcome of AIDS\u2010related Kaposi's sarcoma during highly active antiretroviral therapy","volume":"27","author":"Cattelan AM","year":"2005","journal-title":"Int J Oncol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01465.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-225"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00002"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4072"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200307250-00001"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2011.00955.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2011.00955.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:54:54Z","timestamp":1698641694000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2011.00955.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,24]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1468-1293.2011.00955.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2011.00955.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,24]]}}}